Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership

Novartis enters licensing agreement with UNP for peptide therapeutics

Novartis has signed a research partnership and licensing agreement with Unnatural Products (UNP) valued at up to $1.7bn.

Novartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural Products - European Biotechnology Magazine

California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide therapeutics for an undisclosed cardiovascular program. California-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocycl…

Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership

Novartis will apply Unnatural Products (UNP)’s artificial intelligence (AI)-guided macrocyclic peptide platform to develop next-generation cardiovascular disease therapeutics, through a collaboration that could generate more than $1.8 billion for the Santa Cruz, CA-based biotech. UNP has signed a research collaboration and licensing agreement with Novartis launching the partnership, beginning with an undisclosed program. The collaboration is int…